These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32093511)

  • 21. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
    Diaz AE; Mesa RA
    Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of myelofibrosis after ruxolitinib failure.
    Bose P; Verstovsek S
    Leuk Lymphoma; 2020 Aug; 61(8):1797-1809. PubMed ID: 32297800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
    Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
    Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs for myelofibrosis.
    Atallah E; Verstovsek S
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
    Pepeler MS; Özkurt ZN; Güzel ÖT; Akyürek N
    J Infect Dev Ctries; 2018 Oct; 12(10):926-928. PubMed ID: 32004164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
    Scherber RM; Mesa RA
    Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
    Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
    Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of ruxolitinib for myelofibrosis.
    Santos FP; Verstovsek S
    Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New approaches to tackle cytopenic myelofibrosis.
    Reynolds SB; Pettit K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
    Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
    Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
    Tefferi A; Pardanani A
    Mayo Clin Proc; 2011 Dec; 86(12):1188-91. PubMed ID: 22034658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population.
    Du X; Zhou D
    Front Med; 2016 Dec; 10(4):437-443. PubMed ID: 27858230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK inhibitors in the treatment of myelofibrosis.
    Levavi H; Hoffman R; Marcellino BK
    Clin Adv Hematol Oncol; 2022 Jul; 20(7):456-467. PubMed ID: 35802878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety considerations when treating myelofibrosis.
    O'Sullivan JM; McLornan DP; Harrison CN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
    Bose P; Mesa RA
    Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations.
    Gill H; Leung GMK; Kwong YL
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):667-675. PubMed ID: 38066870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.